To ensure the continuity of biomedical research into rare genetic diseases, we have established two institutes in Italy that have become known and valued worldwide, in addition to a careers programme that invests in talent and fosters the sharing of knowledge among promising young researchers.

449 professional resources
253.300.000 euro invested

Headed by Luigi Naldini, SR-Tiget is a world leader for gene therapy: the therapy for the treatment of ADA-SCID is one of the first examples of effective gene therapy in the world.

Headed by Andrea Ballabio, Tigem is an institute where researchers could focus on studying the mechanisms underlying genetic diseases and on developing innovative therapeutic strategies.

Our careers programme, set up with the support of the Nobel Prize winner Renato Dulbecco, fosters the talents of  young researchers looking to embark on an independent career.

Il tuo browser non è più supportato da Microsoft, esegui l'upgrade a Microsoft Edge per visualizzare il sito.